Impact Events
More| Date | Lead Company |
Event | Type | Approval Change |
Approval Likelihood |
|---|---|---|---|---|---|
| 7/8/21 | Oncopeptides AB (ONCO) | Pepaxto for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/6/21 | Boehringer Ingelheim | Jardiance for Chronic Heart Failure - Preserved Ejection Fraction (Chronic HFpEF) | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/2/21 | Arrowhead (ARWR) | ARO-ENaC for Cystic Fibrosis (CF) | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/2/21 | Provention Bio (PRVB) | Teplizumab for Diabetes Mellitus, Type I | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/1/21 | LG Chem (051910:KS) | LC350189 for Gout | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range |
Lead Company |
Drug | Expected Catalyst |
|---|---|---|---|
| 08/16/19 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
| 06/30/21 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
| 07/09/21 | Subscribers Only | Subscribers Only | Regulatory - PDUFA/Approval Decision (US) |
| 07/09/21 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 07/09/21 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |